Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress
The study involved end-stage oncology patients with no other suitable treatment options. In this Phase Ib study,Pidnarulex (CX-5461) demonstrated acceptable clinical tolerability and showed prelimina